The Annals Evolution of Clinical Pharmacy | Now Available
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     


Published Online, 31 March 2009, www.theannals.com, DOI 10.1345/aph.1L570.
 The Annals of Pharmacotherapy: Vol. 43, No. 5, pp. 920-927. DOI 10.1345/aph.1L570
© 2009 Harvey Whitney Books Company.
This Article
Right arrow Résumé Freely available
Right arrow Extracto Freely available
Right arrow Full Text
Right arrow PDF
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tyler, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tyler, T.

ONCOLOGY

Once-Daily Dasatinib for Treatment of Patients with Chronic Myeloid Leukemia

Timothy Tyler, PharmD FCSHP

Director of Pharmacy Services, Comprehensive Cancer Center, Desert Regional Medical Center, 1180 N. Indian Canyon Dr., E-218, Palm Springs, CA 92262, fax 760/416-4726, TTyler{at}aptiumoncology.com

Reprints: Dr. Tyler

OBJECTIVE: To discuss the new dasatinib dosing regimen for the treatment of chronic phase chronic myelogenous leukemia (CP CML) in patients who failed or were intolerant to imatinib therapy.

DATA SOURCES: Literature published between July 2008 and December 2008 was accessed via MEDLINE, the Proceedings of the American Society of Hematology, and the Proceedings of the American Society of Clinical Oncology using the key words chronic myelogenous leukemia, chronic myeloid leukemia, dasatinib, imatinib, nilotinib, pharmacokinetics, and regimen.

STUDY SELECTION AND DATA EXTRACTION: Meeting abstracts and reports of major Phase 1-3 studies published in English are included.

DATA SYNTHESIS: Imatinib is the standard first-line therapy for CML; however, some patients develop resistance or are intolerant to the drug. Dasatinib was approved for the treatment of imatinib-resistant/intolerant patients with CML or Philadelphia chromosome-positive acute lymphoblastic leukemia at the dosage of 70 mg twice daily. A Phase 3 dose-optimization study was performed to compare this regimen with others, including dasatinib 100 mg once daily, in patients with CP CML. Results of this study showed that there was no significant difference in efficacy between these 2 regimens. The safety profile was improved in the 100-mg once-daily dasatinib arm with significantly reduced frequencies of grade 3-4 thrombocytopenia and all-grade pleural effusions. The number of patients who had to discontinue, reduce, or interrupt their dosage was also less among patients taking dasatinib 100 mg once daily.

CONCLUSIONS: Dasatinib 100 mg once daily has a more favorable risk to benefit assessment compared with the previous 70 mg twice-daily regimen and is now the recommended schedule for patients with CP CML.

Key Words: chronic myelogenous leukemia, chronic myeloid leukemia, dasatinib, regimen, schedule

Published Online, March 31, 2009. www.theannals.com, DOI 10.1345/aph.1L570




homecopy help contact us subscription past issues search current issue
Copyright © 2009 by Harvey Whitney Books Company.